These new data from PALOMA-3 show that adding IBRANCE to fulvestrant led to a substantial improvement in this important area,” said Nicholas Turner, M.D., Ph.D., professor of molecular oncology at The ...
Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine ...
Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. Genomic correlates of response to adjuvant trastuzumab ...
Last year, the United States Food and Drug Administration (FDA) approved palbociclib (Ibrance, Pfizer Inc) in combination with letrozole (Femara, Novartis Pharmaceuticals Corporation) for the ...
Pfizer Inc. today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in ...
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 PALOMA-3 trial for IBRANCE® (palbociclib) met its primary endpoint of demonstrating an improvement in progression-free survival (PFS) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results